RISA Labs, a healthtech startup focused on an AI operating system for oncology, has raised $11.1 million in its Series A funding round co-led by Cencora Ventures and Optum Ventures. The round also saw participation from Oncology Ventures, Z21 Ventures, and John Simon (co-founder of General Catalyst) via his VentureforGood investment entity.
The fresh funds raised will be used to deploy RISA’s system to cancer clinics, health systems, specialty pharmacies, and infusion networks across the United States, changing how complex oncology workflows are managed end-to-end.
Earlier in April last year, RISA Labs raised $3.5 million in a seed funding round led by Flipkart co-founder Binny Bansal, which saw participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and angel investor Ashish Gupta.
Founded in 2024 by Kshitij Jaggi (CEO) and Kumar Shivang (CTO), RISA Labs is the creator of BOSS Console, which helps build an AI OS for mission-critical institutions. Its first area of focus is oncology, where the system unifies access, benefits, and prior authorization across cancer centers, specialty pharmacies, and infusion networks so every eligible patient can start the right therapy faster.
Already deployed at leading oncology networks and community practices, RISA helps them operate with greater efficiency, capacity, and precision while strengthening financial performance: making institutions win in the age of AI.
Kshitij Jaggi, CEO of RISA Labs, said, “In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster and deepening our understanding of the disease for the next patient through data.”
Kumar Shivang, CTO of RISA Labs, said, “BOSS Console is a low-entropy thinking information machine. Modern oncology has created thousands of potential care paths for every patient. It has become essential to have an intelligent operating system that can absorb this complexity, remove administrative burden, and act as a companion to the most informed clinical decisions.”
Jason Dinger, Senior Vice President, Strategic Execution at Cencora, said, “As the treatments available for oncology patients increase in number and complexity, solutions to help streamline operational processes and enable efficient access to therapy become vital. We look forward to supporting RISA on their next phase of growth.”
